TRẠM BIẾN ÁP NHỎ

Trạm biến áp nhỏ gọn Hoàn hảo đến chi tiết cuối cùng Đánh giá lên đến 1000kA Làm bằng thép không gỉ, không cần bảo trì Sản xuất theo tiêu chuẩn IEC 62271-202 Kiểm tra tuân thủ tiêu chuẩn quốc tế

Trạm biến áp nhỏ gọn

  • Hoàn hảo đến chi tiết cuối cùng
  • Đánh giá lên đến 1000kA
  • Làm bằng thép không gỉ, không cần bảo trì
  • Sản xuất theo tiêu chuẩn IEC 62271-202
  • Kiểm tra tuân thủ tiêu chuẩn quốc tế

    Cám ơn bạn đã ghé thăm website của chúng tôi!

    Nếu bạn có bất kỳ thắc mắc, ý kiến hay thông tin nào cần biết về Công ty, vui lòng gửi thông tin cho chúng tôi theo hướng dẫn dưới đây. Chúng tôi luôn sẵn sàng giải đáp.

    Product Features

    • Chất Lượng Cao
      Đánh giá lên đến 1000kA
    • Thiết kế ấn tượng
      Hoàn hảo đến chi tiết cuối cùng. Làm bằng thép không gỉ, không cần bảo trì
    • Công nghệ vượt trội
      Sản xuất theo tiêu chuẩn IEC 62271-202
    • Độ an toàn cao
      Kiểm tra tuân thủ tiêu chuẩn quốc tế

    Best Product For You.
    Check the demo Video

    Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

    Product information

    • Solar water heaters
      The energy in sunlight is in the form of electromagnetic radiation from the infrared (long) to the ultraviolet (short) wavelengths.
    • Solar collectors
      The energy in sunlight is in the form of electromagnetic radiation from the infrared (long) to the ultraviolet (short) wavelengths.
    • Water tanks
      The energy in sunlight is in the form of electromagnetic radiation from the infrared (long) to the ultraviolet (short) wavelengths.
    • Solar powe
      The energy in sunlight is in the form of electromagnetic radiation from the infrared (long) to the ultraviolet (short) wavelengths.

    Along with their colleagues, Dr. Jonathan Loree, a medical oncologist and assistant professor at the University of British Columbia in Vancouver in Canada and Dr. Kanwal Raghav, an associate professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston analyzed 230 oncology clinical trials. These trials took place between 2008–2018 and resulted in the Food and Drug Administration (FDA) approving cancer drugs.

    They found that only 145 (63%) of the 230 trials, included any information about the participant’s race. More specifically, only 18 trials (7.8%) gave a breakdown of the participants by the “four major races in the United States (white, Asian, Black, and Hispanic)” as the authors put it.
    On average, 76.3% of the participants were white, 18.3% Black, 3.1% Asian, and 6.1% Hispanic. In the period that the authors looked at, these percentages changed only marginally.

    Along with their colleagues, Dr. Jonathan Loree, a medical oncologist and assistant professor at the University of British Columbia in Vancouver in Canada and Dr. Kanwal Raghav, an associate professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston analyzed 230 oncology clinical trials. These trials took place between 2008–2018 and resulted in the Food and Drug Administration (FDA) approving cancer drugs.

    They found that only 145 (63%) of the 230 trials, included any information about the participant’s race. More specifically, only 18 trials (7.8%) gave a breakdown of the participants by the “four major races in the United States (white, Asian, Black, and Hispanic)” as the authors put it.
    On average, 76.3% of the participants were white, 18.3% Black, 3.1% Asian, and 6.1% Hispanic. In the period that the authors looked at, these percentages changed only marginally.

    Along with their colleagues, Dr. Jonathan Loree, a medical oncologist and assistant professor at the University of British Columbia in Vancouver in Canada and Dr. Kanwal Raghav, an associate professor in the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston analyzed 230 oncology clinical trials. These trials took place between 2008–2018 and resulted in the Food and Drug Administration (FDA) approving cancer drugs.

    showroom